Avacta Life Sciences Limited
  • About
  • Therapeutics
  • Diagnostics
  • Investors
  • News
  • Careers
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • People
    • Scientific Resources
    • Intellectual Property
    • Virtual tour
  • Therapeutics
    • Therapeutics
    • Affimer®
    • preCISIONTM
    • Pipeline
    • Partnering
    • Clinical trials
    • News
  • Diagnostics
    • Diagnostics
    • Products
    • Affimer®
    • Key benefits
    • Partnering
    • Resources
    • News
  • Investors
    • Investors
    • CEO Welcome
    • Key information
    • Corporate Governance
    • Documents & Presentations
    • Share price
    • RNS News
  • News
  • Careers
    • CEO Welcome
    • Job vacancies
    • About Avacta
    • Benefits of working at Avacta
  • Contact
Home News Investors Page 3
filter by: view all | Blogs | Diagnostics | Investors | Therapeutics

Investors

29 Sep 2021

Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership

Investors | Therapeutics
09 Sep 2021

Notice of Results and Investor Presentation

Investors
06 Sep 2021

Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division

Investors | Therapeutics
02 Sep 2021

Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division

Investors | Therapeutics
18 Aug 2021

Directorate Change

Investors
11 Aug 2021

Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase 1 Clinical Trial

Investors | Therapeutics
04 Aug 2021

Update on AffiDX® SARS-CoV-2 Antigen Lateral Flow Test

Diagnostics | Investors
14 Jul 2021

Avacta’s Diagnostic Division Achieves ISO 13485 Certification

Diagnostics | Investors
29 Jun 2021

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant

Diagnostics | Investors
28 Jun 2021

Result of Annual General Meeting

Investors

Posts navigation

Older posts
Newer posts
Avacta Life Sciences Limited
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Returns & cancellations policy
  • Corporate Responsibility
  • Contact Us

Avacta Diagnostics

Unit 20, Ash Way
Thorp Arch Estate
Wetherby
LS23 7FA
+44 (0)1904 21 7070

virtual tour
email

Avacta Therapeutics

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

Investor Enquiries

FTI Consulting
200 Aldersgate
Aldersgate Street
London
EC1A 4HD

Email

Twitter | Linkedin

©2022 Avacta Life Sciences Limited. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok